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Erythema nodosum (EN) may follow a variety of infections, but in regions with a high prevalence of
tuberculosis, is frequently associated with a positive tuberculin skin test (TST) and tuberculosis infection. We
aimed to investigate the immunological differences between patients with EN as a manifestation of primary
tuberculosis, and those with progressive pulmonary tuberculosis (PTB) or asymptomatic infection. We studied
the inflammatory response to both mycobacterial and non-mycobacterial antigens in 11 children with EN
associated with a positive TST, 22 children with culture-confirmed tuberculosis, and 53 healthy skin test-positive
children. In addition, we evaluated functional anti-mycobacterial immunity using an ex vivo assay of
mycobacterial growth restriction in five children with EN and 15 with PTB. Patients with EN were distinguished
by enhanced mycobacterial growth restriction on the functional assay, which was associated with a markedly
increased production of IFNg in response to stimulation with purified protein derivative of Mycobacterium
tuberculosis. Children presenting with EN and a positive TST show evidence of responses associated with
enhanced anti-mycobacterial immunity.
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INTRODUCTION
Erythema nodosum (EN) is an inflammatory condition
characterized by the presence of tender subcutaneous
nodules distributed symmetrically over the extensor surfaces
of the lower extremities. There are well-described associa-
tions between EN and a number of underlying disorders,
including infections such as tuberculosis, streptococcal
pharyngitis, and Epstein-Barr virus as well as non-infectious
conditions, such as inflammatory bowel disease, lymphoma,
drugs, and sarcoidosis (Cribier et al., 1998). The proportion of
cases associated with a particular underlying etiology varies
widely, with primary tuberculosis being responsible for a
high proportion of cases in regions where tuberculosis is
endemic (Kumar and Sandhu, 2004; Mert et al., 2004). The
Western Cape region of South Africa has among the highest
reported rates of tuberculosis in the world, with an annual
incidence of 967/100,000 in 2004 (Tuberculosis Statistics:
Cape Town. Western Cape Department of Health. http://
www.capegateway.gov.za/Text/2006/5/tb_stats_2006.pdf.
Accessed 20 June 2006).
The pathogenesis of EN remains largely unknown. The
condition is thought to represent a hypersensitivity reaction to
a triggering event. The histological picture of lymphocytes
infiltrating the septa between subcutaneous fat nodules may
provide an important clue as this pattern resembles a
delayed-type hypersensitivity reaction (Fox and Schwartz,
1992). Llorente et al. (1997) have previously demonstrated
elevated IL-2 and IFNg gene expression in peripheral blood
mononuclear cells and skin biopsies of EN patients, suggest-
ing that a polarized Th1 response occurs in EN.
EN is frequently associated with a positive tuberculin skin
test (TST) (Kumar and Sandhu, 2004). As TST reactivity can be
due to previous BCG vaccination or exposure to environ-
mental mycobacteria as well as infection with Mycobacter-
ium tuberculosis, it is unclear whether the reaction in
individual cases of EN reflects a nonspecific heightened
responsiveness to mycobacterial antigens shared by M.
tuberculosis, BCG and environmental mycobacteria, or
whether it is the result of a true underlying tuberculosis
infection.
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The M. tuberculosis-specific antigens ESAT-6 and culture
filtrate protein 10 have been shown to be useful in
distinguishing between tuberculosis infection and prior
BCG vaccination, using either in vitro enzyme-linked
immune spot (ELISPOT) or whole-blood methods to detect
T-cell reactivity (Ewer et al., 2003). To address the role of
tuberculosis infection in the pathogenesis of EN, and to
understand the immunological mechanisms involved, we
studied the cytokine responses to both tuberculosis-specific
and nonspecific antigens in a group of children with EN and a
positive TST, suggesting infection with M. tuberculosis. We
compared these children with a group of children with active
pulmonary tuberculosis (PTB), as well as a group of healthy
TST-positive children. In addition, we used a novel whole-
blood assay, measuring restriction of mycobacterial growth
in vitro, to evaluate functional anti-mycobacterial immune
responses related to the altered cytokine production.
RESULTS
The characteristics of the children with EN together with their
ELISPOT results are given in Table 1. The mean ages of EN
cases and healthy controls were similar (99 and 77 months,
respectively), but older than the PTB cases (24 months,
P¼0.002). For the subset of children in whom the whole-
blood BCG lux assay was performed, the mean age was 48
months in both the PTB and EN groups, but 140 months in the
control group. There appeared to be two distinct groups
within the EN patients, those presenting at a very young age,
and an older group over the age of 8 years. Although the
numbers are small, the age distribution differed from patients
with PTB (Figure 1). Three of the EN children had abnormal
chest radiographs, one showing pneumonic changes together
with hilar lymphadenopathy, one a Ghon focus, and one
suggestive of hilar lymphadenopathy. All ten of the EN
children, those had ELISPOT testing performed, showed
ELISPOT responses to purified protein derivative (PPD), in
keeping with their positive TST results. However, only seven
of these had a positive response to the specific antigen ESAT-6.
Of the children in the younger age cluster, only one of the
four tested had a positive ESAT-6 response, whereas all of
those in the older cluster had a positive response (P¼0.02).
There was no significant difference in cytokine production
between the two age groups.
Table 1. Characteristics of subjects with EN and ELISPOT results
Case number Age (months) Sex Chest radiograph Tuberculin skin test
ELISPOT results (spots per 106
lymphocytes)
PPD ESAT-6 Control
EN1 17 F Normal Mantoux 15 mm 163 47 2
EN21 19 M R upper lobe opacification and hilar
lymphadenopathy
Mantoux 18 mm ND2 ND ND
EN31 20 M Possible hilar lymphadenopathy Mantoux 20 mm 501 12 2
EN41 21 M Normal Tine grade 3 328 0 0
EN5 24 F Normal Mantoux 16 mm 216 3 2
EN61 99 F Normal Tine grade 43 3,090 113 2
EN7 111 F Ghon focus4 Mantoux 15 mm 385 489 32
EN8 116 F Normal Tine grade 4 1,515 112 5
EN91 126 F Normal Mantoux 18 mm 810 346 13
EN10 128 F Normal Tine grade 4 2,260 147 43
EN11 137 F Normal Tine grade 4 59 31 7
1BCG lux assays performed.
2Not done.
3Tine test grading: Negative – No induration; Grade 1 – 4-6 papules (also considered negative); Grade 2 – Confluent papules form indurated ring; Grade 3 –
Central filling to form disc (positive); Grade 4 – Disc 410 mm with or without blistering (strongly positive).
4Pulmonary focus with associated hilar lymphadenopathy.
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Figure 1. Age distribution of children with EN, children with acute PTB and
healthy TSTþ children. Lines represent median values. Children with TSTþ
EN fell into two distinct age groups.
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In the whole-blood assay (Figure 2), children with EN
produced markedly more IFNg in response to M. tuberculosis
PPD, median 36,736 pg/ml) when compared with children
with PTB (6,320 pg/ml, Po0.01) or healthy controls
(11,004 pg/ml, P¼0.002). Tumor necrosis factor (TNF)
responses appeared higher among EN cases (median
1,755 pg/ml) compared with controls (1,002 pg/ml, Po0.05)
and PTB cases (1,157 pg/ml), but this failed to reach statistical
significance (P¼0.069). IL-12p70 production was similar in
EN and PTB cases (median 828 and 786 pg/ml, respectively)
and non-significantly lower in controls (400 pg/ml, P40.05).
Median levels of IL-10 produced in response to PPD were
similar in the EN (78 pg/ml) and healthy children (40 pg/ml).
Children with active PTB tended to produce more IL-10
(median 151 pg/ml, P¼ 0.0194).
The growth of BCG lux was measured in vitro in five
children with EN and compared with 15 children with PTB
and eight healthy control children with TST 415 mm
(Figure 3). A growth ratio (GR) was calculated from this
assay, which reflects the ability of whole blood to restrict
growth of BCG. A low GR implies greater growth restriction.
Blood from children with EN (median GR¼1.5) restricted
growth of BCG in vitro better than blood from children with
PTB (median GR¼5) or healthy TSTþ children (GR¼ 6,
P¼0.01). Previous results from our laboratory confirmed
that there is no age dependency in growth restriction (data
not shown).
DISCUSSION
EN is associated with a strong IFNc response and restriction of
mycobacterial growth ex vivo
Studies in both mice and humans have identified the Th1
axis, with IFNg as a central player, as an important role in
protection against mycobacterial infection (Sullivan et al.,
2005). Individuals with genetic defects in Th1 cytokine
production or response elements are predisposed to severe
infections with both non-tuberculous mycobacteria and
tuberculosis (Newport and Levin, 1999).
It is therefore of interest that blood from children with EN
produced markedly more IFNg in response to stimulation
with PPD when compared with either healthy TSTþ children
or children with culture-confirmed PTB. Children with active
PTB tended to produce the lowest levels of IFNg as expected,
given the poor antigen-specific responses previously docu-
mented among children with active infection (Ellner, 1997).
A further possible explanation for the lower levels of IFNg in
this group is their younger age, given the reduced functional
capacity of T lymphocytes in early life (Wilson et al., 1992).
There was a trend towards increased production of another
Th1 cytokine, TNF, in response to LPS stimulation among EN
patients. In contrast, PPD-stimulated levels of the regulatory
cytokine IL-10 were lower in EN patients and controls than in
PTB cases. This pattern of reactivity, with high levels of the
proinflammatory cytokines IFNg, and TNF, and low levels of
the regulatory cytokine IL-10, suggests that EN is associated
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Figure 2. Cytokine responses (a: IFNg, b: TNF, c: IL12p70, d: IL-10) in whole blood by category. Diluted whole blood was stimulated with PPD
(for measurement of IFNg and IL-10), with LPS (TNF measurement) or LPS plus IFNg (IL-12p70). Cytokines in culture supernatants were measured by ELISA
in children with EN, acute PTB or healthy TSTþ children. Plots show median values with quartiles. Whiskers show highest and lowest values. Blood from
children with EN produced significantly more IFNg in response to PPD than healthy TSTþ children or children with PTB.
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with a more intense pro-inflammatory response than is seen
in PTB.
The second distinctive finding in the children with EN, as
compared with those with PTB or healthy controls, was the
significantly enhanced functional ability of blood to restrict
the growth of mycobacteria ex vivo. We have previously used
this assay to show that BCG vaccination enhances myco-
bacterial growth restriction (Kampmann et al., 2004) and
that growth restriction improves as immune reconstitution
occurs during highly active antiretroviral therapy (Kampmann
et al., 2006). This assay is therefore a useful marker of anti-
mycobacterial immunity and our results suggest that the EN
patients are more able to restrict the growth of mycobacteria
than PTB patients or healthy controls. The control children for
this assay were significantly older than the EN patients.
However, this is unlikely to confound these results, as age
does not significantly affect growth restriction among BCG-
vaccinated children (B Kampmann, unpublished data) (in any
event, the trend might be towards underestimating the
magnitude of any difference, as older children are assumed
to have stronger anti-mycobacterial immunity).
As IFNg and TNF are key cytokines involved in the
activation of macrophages to enhance mycobacterial killing,
these data, together with the increased functional ability to
restrict mycobacterial growth, suggests that EN occurs in
children with strong anti-mycobacterial immunity. These
enhanced responses are apparent in peripheral blood. Further
work examining the precise nature of the immune response at
the site of the lesions is required to relate the circulating
responses to the skin manifestations of EN.
It is interesting to draw a parallel with EN leprosum, an
immunologically mediated reaction to a different mycobac-
terium, Mycobacterium leprae. EN leprosum is also char-
acterized by subcutaneous nodules on the lower extremities
as well as by arthralgias and fever. EN leprosum is
characterized by a Th1 cytokine profile with detectable IFNg
and IL12p40 RNA in unstimulated circulating peripheral
blood mononuclear cells (Sreenivasan et al., 1998). Further,
the treatment of multibacillary leprosy with recombinant
human IFNg is associated with the development of EN
leprosum (Sampaio et al., 1996). In both conditions, there-
fore, the presence of high levels of IFNg (whether endogenous
or exogenous) appears central to the pathogenesis of the
condition.
Older children with EN had positive responses to the
tuberculosis-specific antigen, ESAT-6
The nature of the antigenic stimulus for EN varies according
to geographic location. In South Africa, where tuberculosis is
highly prevalent, tuberculosis is likely to be an important
triggering event. However, BCG vaccine coverage at birth is
in excess of 95% in South Africa (Saloojee and Bamford,
2006). All cases of EN reported completion of vaccination,
however, vaccine records were not available for review in the
majority of cases.
It is therefore feasible that the positive TST documented in
many cases of EN could be associated with a nonspecific
polarized Th1 response to antigens such as BCG or
environmental mycobacteria.
We sought to test this hypothesis by testing ELISPOT
responses to the tuberculosis-specific antigen ESAT-6. Cases
with EN fell into two discrete age clusters with median ages
of 20 and 119 months. Interestingly, younger children
presenting with EN were unlikely to have a positive response
to ESAT-6. We and others (Nicol et al., 2005) have previously
shown that over 80% of children with proven active
tuberculosis have positive ELISPOT responses to tuberculo-
sis-specific antigens. It is possible that the positive TST in this
group of young children may be associated with recent BCG
vaccination, rather than with infection with M. tuberculosis.
An alternative explanation is that the development of specific
IFNg responses is delayed in the younger children. Several
studies indicate an age-related increase in IFNg responses
(Hartel et al., 2005), and the lack of ELISPOT response thus
may reflect this age-related delay in maturation. However,
we believe that this is an unlikely explanation, given the
strong ELISPOT responses to PPD but not ESAT-6 in these
children, suggesting that EN in these cases was unlikely to
have been due to recent tuberculosis infection.
In contrast, all six children with EN in the older group had
a positive response to ESAT-6, suggesting that the precipitat-
ing stimulus in these cases was recent infection with M.
tuberculosis. Currently, most tuberculosis-specific ELISPOT
assays employ two specific antigens, ESAT-6 and culture
filtrate protein 10. One drawback of this study was that only
ESAT-6 was used for testing. It is feasible that additional cases
would have responded to culture filtrate protein 10, had this
antigen been available. Furthermore, repeat of the ELISPOT
after a delay of 1–2 months, may have helped to establish
whether the specific response was delayed rather than
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Figure 3. BCG lux GRs by category. Diluted whole blood was incubated with
BCG lux for 96 hours and the GR calculated using the formula: luminescence
at 96 hours/luminescence at 0 hour. Children with EN, acute PTB and healthy
TSTþ children. Lines represent median values. Blood from children with EN
restricted the growth of BCG lux significantly more than healthy TSTþ
children or children with PTB.
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absent. In vitro IFNg-release assays that are able to
discriminate between prior BCG vaccination and tuberculosis
infection may, therefore, play an adjunctive role in the
clinical evaluation of children with a positive TST and EN.
When a child presents with EN, a positive TST and no
other clinical, radiological, or microbiological evidence of
tuberculosis, the differentiation between tuberculosis infec-
tion and active disease is unclear. The presence of EN and a
positive TST always requires a careful clinical examination
and chest radiograph to determine whether there is under-
lying active disease.
In summary, blood from children with EN and a positive
TST shows an enhanced ability to restrict growth of
mycobacteria ex vivo and marked production of IFNg in
response to PPD when compared to both children with
active PTB as well as healthy skin test-positive children.
These are features associated with strong anti-mycobacterial
immunity. Older children with EN were more likely to
have positive responses to the tuberculosis-specific antigen
ESAT-6, suggesting recent tuberculosis infection.
MATERIALS AND METHODS
Subjects
Eleven children (o14 years of age) presenting to the dermatology
outpatient clinic with EN and positive TST were investigated. They
were compared with children with newly diagnosed PTB within the
first 3 weeks of therapy and with 53 healthy children with a TST
(Mantoux) skin test ofX15 mm recruited from the same community.
Two groups of children with PTB were recruited. The first PTB group
of 22 children with culture-confirmed tuberculosis was used for
comparison of cytokine responses using ELISPOT and stimulated
whole-blood culture supernatants. A second group of 15 children
with PTB was enrolled for comparison of mycobacterial growth in
whole blood, as the volumes of blood required precluded under-
taking both assays on the same patients. TST-positive healthy
children were recruited by visiting homes of adults with previously
diagnosed smear-positive tuberculosis. The decision to place a child
on anti-tuberculous therapy was made by the attending clinician and
was not influenced by the study results. All healthy controls with
positive TST were referred to their local clinic for investigation and
management according to the National Tuberculosis Control
Programme guidelines. Following the consent procedure, 5–10 ml
of blood was collected from each child by peripheral venipuncture.
Approval to undertake the study was obtained from the Research
Ethics Committee of the University of Cape Town and informed
consent obtained from a parent or main caregiver before inclusion in
the study. The study was conducted according to the Declaration of
Helsinki Principles.
Among the children with EN, whole-blood cytokine assays were
performed in all cases. Sufficient blood was available for ELISPOT
assays in ten of the 11 children. In five of the children with EN,
adequate blood was available to perform BCG lux growth assays.
TST of controls was performed by a study nurse, using two
tuberculin units of PPD RT23 (Statens Serum Institute, Copenhagen,
Denmark) and induration diameters measured 48–72 hours later. TST
of children with EN (Mantoux or tine testing) was performed by the
attending clinician (the TST method varied with the hospital where
the children were recruited).
Whole-blood assay for TNF, IL-12p70 IL-10 and IFNc
measurements
We used a range of assays designed to probe the integrity of the IFN-
g/IL-12 response pathway by measuring the production of key
cytokines important in the inflammatory response to mycobacteria.
Whole blood, collected into preservative-free heparin, was diluted
1:10 in RPMI supplemented with penicillin and streptomycin plus
2 mM L-glutamine (Gibco BRL, Paisley, Scotland) and 180 ml pipetted
into 96-well, round-bottomed tissue culture plates (Nunc, Roskilde,
Denmark). For each condition, four wells were used and super-
natants pooled. For measurement of IL-12p70, 10 ml of rHu
IFN-g (final concentration 1 mg/ml) was added, incubated at
371C in 5% CO2 for 2 hours after which 20ml of LPS from
Escherichia coli 0111:B4 (final concentration 10 ng/ml) was
added. Incubation was continued for a further 18 hours at 371C
in 5% CO2. For measurement of TNF, LPS (final concentration
0.5 ng/ml) was used and supernatant harvested after 18 hours.
For IFNg and IL-10 measurement, PPD (Evans Pharmaceutical,
Weybridge, Surrey, UK) at a final concentration of 10 mg/ml was
used as a stimulant and incubated for 6 days. All supernatants were
stored at 801C.
IFN-g, IL-10, TNF, and IL-12p70 were measured by ELISA using
antibody pairs purchased from BD Pharmingen. Results are
expressed as the mean of duplicate readings for each sample, with
a coefficient of variation of less than 15%.
ELISPOT assays
The number of T cells specifically reacting to the tuberculosis-
specific antigen ESAT-6 or the less specific antigens in PPD were
evaluated using the ELISPOT assay performed as described
previously (Lalvani et al., 2001). Briefly, peripheral blood mono-
nuclear cells were separated by Ficoll-Paque centrifugation. Cells
were washed, re-suspended, and counted.
PVDF-backed plates (96-well) (MAIPS4510, Millipore, Bedford,
MA) were coated with 15 mg/ml of anti-IFN-g mAb 1-D1K (Mabtech,
Nacka, Sweden). Cells (300,000 or 100,000 per well) were added to
duplicate wells containing 5 mg/ml ESAT-6 (Statens Serum Institut,
Copenhagen), 10 mg/ml PPD (Evans Vaccines, UK) or mitogen (PHA,
5mg/ml). No antigen was added to the background control wells.
After 18 hours incubation, plates were washed. Biotinylated anti-
IFN-g mAb (100ml of 1 mg/ml), 7-B6-1-biotin (Mabtech), was added
for 2 hours. Plates were then washed and streptavidin-alkaline
phosphatase toxoid (Mabtech) was added. After 1.5 hours and further
washing, 100ml of chromogenic alkaline phosphatase substrate
(Biorad, Hercules, CA) was added. After 10–15 minutes, plates were
washed and spots enumerated independently by two observers using
a stereomicroscope. The mean values of the two observers (mean
inter-observer coefficient of variation¼ 8%) and both duplicate wells
are used in all calculations. Observers were blinded to the clinical
status of the patient.
Whole-blood BCG lux assay
The functional ability to restrict the growth of mycobacteria was
evaluated using the whole-blood luciferase-tagged BCG (BCG lux)
assay as previously described (Kampmann et al., 2004). Briefly,
triplicate samples of heparinized venous blood, diluted with an
equal volume of RPMI were infected with 1 107 relative light units
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(RLU)/ml (equal to 1 106 colony-forming units (CFU)/ml) of BCG
lux and incubated for 96 h with continuous mixing of the samples.
Following lysis of red blood cells, mycobacterial viability was
measured at time of inoculation (T0) and at 96 h (T96) using a
luminometer (Berthold). The GR was calculated using the formula
GR¼RLU of BCG lux at T96/RLU of BCG lux at T0.
Statistical analysis
A response which was 430 spots per million peripheral blood
mononuclear cells and greater than twice the response in the
negative control wells was regarded as positive for ELISPOT analysis.
For comparison of ages and cytokine responses in each group the
Kruskal–Wallis test was used together with Dunn’s post test. Fisher’s
exact test was used for contingency analysis of the number of
positive ELISPOT responses in each age category. For comparison of
GRs the Mann–Whitney test was used. A P-value of less than 0.05
was regarded as significant for all tests.
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